CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy

<div><b>Overall survival</b>. Figure <a href="../fig1/">1</a> depicts the overall survival curves for patients with CDK9 positive versus CDK9 negative tumors. This shows a statistically nonsignificant difference in survival. However, there is a trend for increased overall survival in the group of patients with positive CDK9.</div>

International Journal of Breast Cancer

fig1

Figure 1

Figure 1: CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy 

Figure 1 | CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy 